Segesterone acetate/ethinylestradiol

Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen.[1][2][3] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][4]

Segesterone acetate/ethinylestradiol
Ethinylestradiol (top) and
segesterone acetate (bottom)
Combination of
Segesterone acetateProgestogen
EthinylestradiolEstrogen
Clinical data
Trade namesAnnovera
Other namesEE/SGA; EE/SA
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa604032
License data
Routes of
administration		Intravaginal
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[5] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.[1]

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.[4][6]

See also

References
  1. "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
  2. Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.
  3. Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.
  4. "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control". TherapeuticsMD Inc (Press release). 10 August 2018. Retrieved 10 October 2020.
  5. "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDS) (Press release). 10 August 2018. Retrieved 10 October 2020.
  6. "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.